Cancer Research Wales

The following selected references relate to key CRW-funded projects, listed by author:

Geriant Lewis
Cufflin RS, Spezi E, Millin AE and Lewis DG (2010) ‘An investigation of the accuracy of Monte Carlo portal dosimetry for verification of IMRT with extended fields’ Physics in Medicine and Biology 55 4589-4600

Millin AE & Lewis DG (2009) ‘Routine Dosimetric Verification of Stereotactic Treatments Using Monte Carlo Methods in a Distributed Computing Environment’ Radiosurgery (Basel: Karger) 28-43

Spezi E & Lewis DG (2008) ‘Monte Carlo Treatment Planning for Radiotherapy’ Radiation Protection & Dosimetry 131(1) 123-129

Chin PW, Lewis DG and Giddy JP (2005) ‘A Monte Carlo solution for external beam photon radiotherapy verification’ in The Monte Carlo Method: Versatility Unbounded in a Dynamic Computing World (Oak Ridge: American Nuclear Society, ISBN 0-89448-695-0

Chin PW, Lewis DG and Spezi E (2004) ‘Correction for dose-response variation in a scanning liquid ion chamber EPID as a function of linac gantry angle’ Physics in Medicine and Biology 49(8) N93-N103

Chin PW, Spezi E and Lewis DG (2003) ‘Monte Carlo simulation of portal dosimetry on a rectilinear voxel geometry: a variable gantry angle solution’ Physics in Medicine and Biology 48(16) N231-N238

Spezi E, Lewis DG and Smith CW (2002) ‘A DICOM-RT based Toolbox for the Evaluation and Verification of Radiotherapy Plans’ Physics in Medicine and Biology 47(23) 4223-4232

Spezi E and Lewis DG (2002) ‘Full Forward Monte Carlo Calculation of Portal Dose from MLC Collimated Treatment Beams’ Physics in Medicine and Biology 47(3) 377-390

Spezi E, Lewis DG and Smith CW (2001) ‘Monte Carlo simulation and dosimetric verification of radiotherapy beam modifiers’ Physics in Medicine and Biology 46(11) 3007-3029

Love PA, Lewis DG, Al-Affan IAM, Smith CW (1998) ‘Comparison of EGS4 and MCNP Monte Carlo codes when calculating radiotherapy depth doses’ Physics in Medicine and Biology 43(5) 1351-1357

Andrew Westwell
Daniels S, Tohid SFM, Velanguparackel W, Westwell AD (2010). The role and future potential of fluorinated biomarkers in Positron Emission Tomography. Expert Opinion on Drug Discovery, 5, 291-304.

Tracey Martin
Martin TA and Jiang WG. Claudin-16/paracellin-1, cloning, expression and its role in tight junctions in cancer and endothelial cells. Protocols in Molecular Biology, 2011 in press
Martin TA, Harrison GM, Mason MD, Jiang WG. The Hepatitis A virus Cellular Receptor, HAVcR-1, reduces the integrity of human endothelial tight junctions. Anticancer Research, 2011, in press

Martin TA, Mansel RE, Jiang WG, Loss of occludin leads to the progression of human breast cancer Int J Mol Med , Volume 26 , 5 (November 2010) pp.721-732
Martin TA, Jiang WG, Hepatocyte Growth Factor and Its Receptor Signalling Complex as Targets in Cancer Therapy Anti-Cancer Agent Me , Volume 10 , 1 (January 2010) pp.2-6

Martin TA, Jiang WG, Hepatocyte Growth Factor and cMET, New Development in Cancer Therapies Anti-Cancer Agent Me , Volume 10 , 1 (January 2010) pp.1-1
Martin TA, Pereira G, Watkins G, Mansel RE, Jiang WG. N-WASP is a putative tumour suppressor in breast cancer cells, in vitro and in vivo, and is associated with clinical outcome in patients with breast cancer. Clin Exp Metastasis. 2008;25(2):97-108.

Martin TA, Harrison GM, Watkins G, Jiang WG. Claudin-16 reduces the aggressive behavior of human breast cancer cells. J Cell Biochem. 2008 Sep 1;105(1):41-52.

Sanders AJ, Parr C, Martin TA, Lane J, Mason MD, Jiang WG. Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation. J Cell Physiol. 2008 Sep;216(3):780-9.

Jiang WG, Martin TA, Lewis-Russell JM, Douglas-Jones A, Ye L, Mansel RE. Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome. Mol Cancer. 2008 Sep 16;7:71.PMID: 18796137

Sanders AJ, Parr C, Davies G, Martin TA, Lane J, Mason MD, Jiang WG.Genetic reduction of matriptase-1 expression is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo. Exp Ther Oncol. 2006;6(1):39-48.

Jane Wakeman
Sarkar D, Shields B, Davies M, Muller J & Wakeman J, (2011), Brachyury confers cancer stem cell characteristics on colorectal cancer cells, International Journal Cancer, In Press.

Aled Clayton
Webber, J., R. Steadman, Z. Tabi, Mason MD, and A. Clayton. 2010. Cancer exosomes activate fibroblast to myofibroblast differentiation in a TGF dependent manner. Cancer Res 70:9621-9630.

Welton, J. L., S. Khanna, P. J. Giles, P. Brennan, I. A. Brewis, J. Staffurth, M. D. Mason, and A. Clayton. 2010. Proteomic analysis of bladder cancer exosomes. Molecular & Cellular Proteomics 9:1324-1338.

Tabi Z, Spary LK, Coleman S, Clayton A, Mason MD, Staffurth J. Resistance of CD45RA- T cells to apoptosis and functional impairment, and activation of tumor-antigen specific T cells during radiation therapy of prostate cancer. 2010. J Immunol. 185(2):1330-9.

Mitchell, P. J., J. Welton, J. Staffurth, J. Court, M. D. Mason, Z. Tabi, and A. Clayton. 2009. Can urinary exosomes act as treatment response markers in prostate cancer? J Transl Med 7.

Clayton, A., and M. Mason. 2009. Exosomes in Tumour Immunity. Current Oncology Editorial 16:46-49.

Clayton, A., Mitchell, J. P., Court, J., Linnane, S., Mason, M. D. & Tabi, Z. Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression. J Immunol 2008; 180:7249-7258.

Mitchell, J. P., J. Court, M. D. Mason, Z. Tabi, and A. Clayton. 2008. Increased exosome production from tumour cell cultures using the Integra CELLine Culture System. J Immunol Methods 335:98-105.

Clayton, A., J. P. Mitchell, J. Court, M. D. Mason, and Z. Tabi. 2007. Human tumour-derived exosomes selectively impair lymphocyte responses to Interleukin-2. Cancer Res 67:7458-7466.

Théry, C., A. Clayton, S. Amigorena, and G. Raposo. 2006. Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids. Current Protocols in Cell Biology UNIT 3.22.

Coleman, S., A. Clayton, M. Mason, B. Jasani, M. Adams, and Z. Tabi. 2005. Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Res 65:7000-7006.

Clayton, A., A. Turkes, N. Hossein, M. D. Mason, and Z. Tabi. 2005. Inducible heat shock protein expression in B cell exosomes. J Cell Sci 118:3631-3638.

Clayton, A., and Z. Tabi. 2005. Exosomes and the MICA-NKG2D system in cancer. Blood Cells Mol Dis 34:206-213.

Navabi, H., D. Croston, J. Hobot, A. Clayton, L. Zitvogel, B. Jasani, R. Bailey-Wood, K. Wilson, Z. Tabi, M. D. Mason, and M. Adams. 2005. Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells Mol Dis 35:149-152.

Clayton, A., A. Turkes, S. Dewitt, R. Steadman, M. D. Mason, and M. B. Hallett. 2004. Adhesion and signalling by B cell-derived exosomes: the role of integrins. FASEB J. 18:977-979.

Clayton, A., C. L. Harris, J. Court, M. D. Mason, and B. P. Morgan. 2003. Antigen presenting cell exosomes are protected from complement mediated lysis by expression of CD55 and CD59. Eur J Immunol 33:552-531.

Clayton, A., J. Court, H. Navabi, M. Adams, M. D. Mason, J. A. Hobot, G. R. Newman, and B. Jasani. 2001. Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry. J Immunol Methods 247:163-174.

Steve Man
Nunes CT, Miners KL, Dolton G, Pepper C, Fegan C, Mason MD, Man S (2011). A novel tumor antigen derived from enhanced degradation of bax protein in human cancers. Cancer Res. 71:5435-44.

MS Campo; SV Graham; MS Cortese; GH Ashrafi; EH Araibi; E Dornan; KL Miners; CT Nunes and S Man (2010). HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology 407:137-42.

Z.Tabi and S. Man (2008). Cancer vaccines and immune monitoring (overview). Ch1.8 p129-159. Methods of Cancer Diagnosis, Therapy and Prognosis. Vol 2. (Ed Hayat). Springer Scientific. Dordrecht.
Z Tabi and S. Man (2006). Challenges in cancer vaccine development. Advanced Drug Delivery Reviews. 58, 902-915

S. Man and Z Tabi (2006). Human cancer vaccines (preface). Advanced Drug Delivery Reviews. 58, 899-9
US patent number US2009317415 (A1) awarded 24th December 2009.
S Man, M Mason, and C Nunes. HPV vaccine containing peptides from host cell proteins (for Bax peptides

Zsuzsanna Tabi
Webber J, Steadman R, Tabi Z, Mason MD, Clayton A (2010) Tumour-derived exosomes induce TGF- dependent fibroblast to myofibroblast differentiation. Cancer Res 70:9621-9630.

Tabi Z, Spary LK, Coleman S, Clayton A, Mitchell JP, Mason MD, Staffurth J (2010) Resistance of CD45RA- T cells to apoptosis and functional impairment and generation of tumor-antigen specific T cell responses during radiation therapy of prostate cancer J Immunol 185:1330-1339.

Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z (2008) Human tumour-derived exosomes downmodulate NKG2D expression. J Immunol 180:7249-7258.

Mitchell PJ, Court L, Mason DM, Tabi Z, Clayton A (2007) Human tumour-derived exosomes selectively impair lymphocyte responses to Interleukin-2. Cancer Res 67:7458-7466.

Tabi Z, Man S (2006) Challenges for cancer vaccine development. Adv Drug Delivery Rev 58:902-915.
Coleman S, Clayton A, Mason DM, Jasani B, Adams M, Tabi Z (2005) Recovery of CD8+ T cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Res 65:7000-7006.

Mererid Evans
Evans M and Powell N (2010) . The Changing Aetiology of Head and Neck Cancer: The Role Of Human Papillomavirus (HPV). Clinical Oncology, 22:538-546.

Emiliano Spezi
Spezi E., Special section: Selected papers from the second European workshop on Monte Carlo treatment planning (MCTP2009) Phys. Med. Biol. (2010), 55: (Editorial)

Cufflin RS, Spezi E, Millin AE, and Lewis DG. An investigation of the accuracy of Monte Carlo portal dosimetry for verification of IMRT with extended fields. Phys. Med. Biol. (2010), 55:4589-4600.

Downes P, Jarvis R, Radu E, Kawrakow I, Spezi E. Monte Carlo simulation and patient dosimetry for a kilovoltage cone-beam CT unit. Med. Phys. (2009), 36: 4156-4170.

Downes P, Yaikhom G, Giddy JP, Walker DW, Spezi E, and Lewis DG. High-performance computing for Monte Carlo radiotherapy calculations Phil Trans R Soc A (2009); 367:2607-2617.

Downes P and Spezi E. Simulating oblique incident irradiation using the BEAMnrc Monte Carlo code. Phys. Med. Biol. (2009) 54 N93-N100.

Spezi E, Downes P, Radu E, Jarvis R. Monte Carlo simulation of an x-ray volume imaging cone beam CT unit. Med. Phys. (2009) 36: 127-36.

Spezi E and Lewis DG. An overview of Monte Carlo treatment planning for radiotherapy. Radiat. Prot. Dosim. (2008) 131: 123-9.

Chin PW, Lewis DG, Spezi E. Correction for dose-response variations in a scanning liquid ion chamber EPID as a function of linac gantry angle. Phys. Med. Biol. (2004) 49: N93-N103.

Chin PW, Spezi E, Lewis DG. Monte Carlo simulation of portal dosimetry on a rectilinear voxel geometry: a variable gantry angle solution. Phys. Med. Biol. (2003) 48: N231-N238.

Spezi E. A Monte Carlo investigation of the accuracy of intensity modulated radiotherapy.Med. Phys. (2003) 31: 684

Spezi E, Lewis DG, Smith CW. A DICOM-RT based toolbox for the evaluation and verification of radiotherapy plans. Phys. Med. Biol. (2002) 47: 4223-4232.

Flampouri S, Evans PM, Verhaegen F, Nahum AE, Spezi E, Partridge M. Optimisation of accelerator target and detector for portal imaging using Monte Carlo simulation and experiment. Phys. Med. Biol. (2002) 47: 3331-3349.

Spezi E and Lewis DG. Full forward Monte Carlo calculation of portal dose from MLC collimated treatment beams. Phys. Med. Biol. (2002) 47: 377-390.

Spezi E, Lewis DG, Smith CW. Monte Carlo simulation and dosimetric verification of radiotherapy beam modifiers. Phys. Med. Biol. (2001) 46: 3007-3029.

Malcolm Mason
Ye L, Mason MD, Jiang WG (2011) Bone morphogenetic protein and bone metastasis, implication and therapeutic potential. Front Biosci 16:898-936.

Sanders AJ, Ye L, mason MD, Tabi Z, Clayton A (2010) The impact of EPLINα (Epithelial protein lost in neoplasm) on endothelial cells, angiogenesis and tumorigenesis. Angiogenesis 13:317-26.

Lane J, Martin TA, McGuigan C, Mason MD, Jiang WG (2010) The differential expression of hCNT1 and hENT1 in breast cancer and the possible impact on breast cancer therapy. J Exp Ther Oncol. 8:203-10.

Shelley MD, Mason MD, Kynaston H (2010) Intravesical therapy for superficial bladder cancer: a systemic review of randomised trails and meta-analysis. Cancer Treat Rev 36:195-205.

Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR (2009) Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival resuts from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol. 10:872-876.

Shelley MD, Kumar S, Coles B, Wilt T, Staffurth J, Mason MD (2009) Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials. Cancer Treat Rev 36:540-546.

James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Anderson J, Popert RJ, Sanders K, Morgan RC, Stansfeld J, Dwyer J, Masters J, Parmar MK (2009) Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomised controlled trial. BJU Int 103:464-469.

Jiang WG, Ablin RJ, Kynaston HG, Mason MD (2009) The prostate transglutaminase (TGase-4, TGaseP) regulates the interaction of prostate cancer and vascular endothelial cells, a potential role for the ROCK pathway. Microvasc Res. 77:150-157.

Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD (2009) A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev. 35:9-17.

Coleman S, Gibbs A, Butchart E, Mason MD, Jasani B, Tabi Z (2008) SV40 large T antigen-specific human T cell memory responses. J Med Virol. 80:1497-1504.

You can apply for funding for your research project by downloading a Research_Application_Form here.